$12.1m pumped into nerve regeneration co:
This article was originally published in Clinica
AxoGen, the Alachua Florida-based company commercialising peripheral nerve regeneration technologies, has completed a $12.1m series C round. Participants in the financing included Accuitive Medical Ventures, Cardinal Partners, De Novo Ventures and Springboard Capital II. AxoGen launched its Avance nerve graft in July 2007 and intends to use the proceeds for sales and marketing activities. The product is a human allograft nerve that is minimally processed to preserve the natural 3D structure of the nerve basal lamina and the inherent growth promoters within it.
You may also be interested in...
Organizations like BARDA, CEPI and others are looking to partner with industry to rapidly test, manufacture, package and deploy vaccines and therapeutics, identifying areas they want to work together during BIO’s recent summit.
The economic stress on payers caused by the pandemic will cause a setback in the development of payment approaches for regenerative therapy, Blue Cross Blue Shield executive warns.
An interim final rule posted by the CMS this week widens further a series of telehealth exemptions and lab specimen collection payment provisions it has previously issued to help providers during the COVID-19 pandemic.